A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Effects of Single Doses of NaV1.8 Inhibitors on C-Nociceptor Action Potentials in Healthy Adults
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Suzetrigine (Primary) ; VX 150 (Primary)
- Indications Pain
- Focus Pharmacodynamics
- Sponsors Vertex Pharmaceuticals
- 16 Jan 2025 Planned number of patients changed from 40 to 92.
- 16 Jan 2025 Planned End Date changed from 1 Sep 2025 to 18 Apr 2025.
- 16 Jan 2025 Planned primary completion date changed from 1 Sep 2025 to 31 Mar 2025.